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Background
Cytotoxic chemotherapy is the standard treatment in
most cancer patients with advanced stage. However,
many patients suffer from severe side effects even if the
anti-cancer treatment is effective. There is no estab-
lished strategy to prevent wide range of side effects of
cytotoxic chemotherapy including acute renal injury.
Cisplatin is a highly effective chemotherapeutic agent
used to treat various malignancies, but its utility is com-
promised by its nephrotoxicity. C-type natriuretic pep-
tide (CNP), a member of the natriuretic peptide family,
exhibits anti-inflammatory effects by activating its speci-
fic receptor, guanylyl cyclase (GC)-B. CNP and GC-B
receptor are known to be expressed in both the vascular
endothelium and kidney. However, there is no evidence
about CNP protection against tissue injury by cisplatin,
which is a representative cytotoxic agent for most can-
cer treatment. This study was designed to examine
whether CNP pre-treatment attenuates tissue injury
including acute renal failure induced by cisplatin.
Methods
We used C57/B6 mice which were pre-treated with saline
or CNP (subcutaneously via osmotic-pump, 2.5μg/kg/min)
and administered intraperitoneally a dose of 20 mg/kg cis-
platin as the experimental acute renal failure mode. CNP
infusion was started one day before the administration of
cisplatin. This dose does not change blood pressure and
heart rate in mice. At 72 hours after cisplatin injection,
urine, blood and kidney samples were collected. Urine and
blood samples were examined biochemically. Histological
findings and gene expression in kidney tissue were
evaluated.
Results
CNP reduced histological renal tubular damage and apop-
tosis induced by cisplatin, and suppressed plasma blood
urea nitrogen (162 ± 34 vs. 63.0 ± 9.9 mg/dL, p < 0.05)
and creatinine levels (1.11 ± 0.44 vs. 0.10 ± 0 mg/dl, p <
0.05), which were elevated by cisplatin administration.
CNP treatment decreased the expression of kidney injury
molecule-1 (by 58.6%, p < 0.05) and monocyte chemoat-
tractant protein-1 (by 67.6%, p < 0.05), which were ele-
vated in the kidney by cisplatin administration. CNP
treatment attenuated the decrease in GC-B expression in
cisplatin-induced kidney injury.
Conclusions
The present study is the first to show that CNP inhibits
nephrotoxicity and kidney cell damage induced by cispla-
tin. Our data provide novel insights into the prophylactic
therapy for various side effects induced by cytotoxic che-
motherapy in many cancer patients.
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